TG Therapeutics, Inc. (TGTX)

17.12 -0.06 (-0.35%) 收市：04:00PM EDT

TG Therapeutics, Inc.

3020 Carrington Mill Blvd.
Suite 475
Morrisville, NC 27560
United States
212 554 4484
https://www.tgtherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 284

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Michael S. Weiss Esq.	Chairman, CEO & President	1.97M	無	1966
Mr. Sean A. Power CPA	CFO, Corporate Secretary & Treasurer	670.58k	無	1982
Jenna Bosco	Senior Vice President of Corporate Communications	無	無	無
Mr. Adam Waldman	Chief Commercialization Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

公司管治

截至 2024年5月1日 止，TG Therapeutics, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：5；董事會：10；股東權利：5；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。